Dystrophin is widely thought to mechanically link the cortical cytoskeleton with the muscle sarcolemma. Although the dystrophin homolog utrophin can functionally compensate for dystrophin in mice, recent studies question whether utrophin can bind laterally along actin filaments and anchor filaments to the sarcolemma. Herein, we have expressed full-length recombinant utrophin and show that the purified protein is fully soluble with a native molecular weight and molecular dimensions indicative of monomers. We demonstrate that like dystrophin, utrophin can form an extensive lateral association with actin filaments and protect actin filaments from depolymerization in vitro. However, utrophin binds laterally along actin filaments through contribution of acidic spectrin-like repeats rather than the cluster of basic repeats used by dystrophin. We also show that the defective linkage between costameric actin filaments and the sarcolemma in dystrophin-deficient mdx muscle is rescued by overexpression of utrophin. Our results demonstrate that utrophin and dystrophin are functionally interchangeable actin binding proteins, but that the molecular epitopes important for filament binding differ between the two proteins. More generally, our results raise the possibility that spectrin-like repeats may enable some members of the plakin family of cytolinkers to laterally bind and stabilize actin filaments.
INTRODUCTION
Costameres are assemblies of cytoskeletal and integral membrane proteins that physically connect the sarcolemmal membrane to the force-generating sarcomeric apparatus at the Z-line in striated muscle . The dystrophin-glycoprotein complex is one element of costameres (Ervasti et al., 1990; Ervasti and Campbell, 1991; Porter et al., 1992; Ervasti and Campbell, 1993; Williams and Bloch, 1999) that is thought to mechanically stabilize the sarcolemmal membrane from shear stresses imposed during eccentric muscle contraction (Petrof et al., 1993; Straub et al., 1997) . Biochemical studies have demonstrated that dystrophin contains two distinct and spatially separated actin binding sites located at the amino terminus and within the middle third of the large rod domain (Rybakova et al., 1996; Amann et al., 1998) . The two actin binding sites of dystrophin form an extended lateral contact with actin filaments and protect them from depolymerization in vitro (Rybakova et al., 1996; Rybakova and Ervasti, 1997) . More recently, we demonstrated that dystrophin is necessary for a mechanically strong physical link between the sarcolemma and actin filaments of costameres (Rybakova et al., 2000) .
Utrophin is a widely expressed autosomal gene product with high sequence similarity to dystrophin (Tinsley et al., 1992) . Utrophin is distributed throughout the sarcolemma in fetal and regenerating muscle, but is down-regulated in normal adult muscle and restricted to the myotendinous and neuromuscular junctions (Blake et al., 1996) . Because utrophin and dystrophin bind the same complement of proteins (Matsumura et al., 1992; Kramarcy et al., 1994; Winder et al., 1995) , it was hypothesized that utrophin may be capable of compensating for dystrophin deficiency. Indeed, transgenic overexpression of utrophin in dystrophin-deficient mdx mice resulted in full recovery for all known parameters of the dystrophic phenotype (Tinsley et al., 1998) . Based on these promising results, utrophin up-regulation or gene therapy is under intense investigation as a potential therapy for Duchenne muscular dystrophy. Recent results, however, have raised concern about whether utrophin can effect the same mechanically strong link with costameric actin as provided by dystrophin (Rybakova et al., 2000) . Although endogenous utrophin expression is up-regulated in striated muscle of mdx mice (Matsumura et al., 1992; Porter et al., 1998) and partially attenuates the phenotype associated with dystrophin deficiency (Deconinck et al., 1997a; Grady et al., 1997) , this level of utrophin expression was not sufficient to retain costameric actin filaments on mechanically isolated sarcolemma (Rybakova et al., 2000) . In addition, sequence comparisons (Winder, 1997; Amann et al., 1999) and biochemical analysis of recombinant protein fragments (Winder et al., 1995; Amann et al., 1998 Amann et al., , 1999 Renley et al., 1998; Moores and Kendrick-Jones, 2000) have indicated that dystrophin and utrophin may bind F-actin through distinct mechanisms. Most notably, utrophin lacks the actin binding region composed of basic spectrin-like repeats that is present in the middle rod domain of dystrophin (Amann et al., 1999) . These data suggested that utrophin may bind actin filaments solely through its amino-terminal calponin homology domain, and with an order of magnitude lower affinity (Winder et al., 1995; Moores and Kendrick-Jones, 2000) compared with dystrophin (Rybakova et al., 1996) .
Herein, we have expressed full-length recombinant utrophin and show that the protein exhibits a native molecular weight and molecular dimensions indicative of a monomer. Contrary to expectations, full-length utrophin bound laterally along actin filaments with high affinity and protected filaments from depolymerization in vitro. Compared with dystrophin, utrophin made less extensive lateral contact with actin filaments and through distinct molecular epitopes. We also demonstrate that costameric actin is rescued on mechanically isolated sarcolemma from transgenic mdx mice that overexpress utrophin (Tinsley et al., 1998) . Our results indicate that utrophin can perform all the actin binding functions documented for dystrophin. These data strongly support the continued exploration of therapies aiming to treat Duchenne muscular dystrophy through interventions that increase utrophin expression.
MATERIALS AND METHODS

Recombinant Utrophin
The 11-kb BamHI/XbaI fragment from a vector encoding full-length mouse utrophin with an amino-terminal FLAG epitope (Guo et al., 1996) was ligated into the BamHI/XbaI site of pFASTBAC1 donor plasmid. The recombinant plasmid was transformed into DH10BAC cells for site-specific transposition into bMON14272 bacmid DNA. High-titer viral stocks were used to infect 5 ϫ 177-cm 2 Sf21 cell monolayers, which were harvested 72 h postinfection and resuspended in 10 ml of 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, and a cocktail of protease inhibitors (Rybakova et al., 1996) . The lysate was circulated over a 2-ml anti-FLAG M2 agarose column (Sigma-Aldrich, St. Louis, MO), which was washed extensively with buffer A (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.1% Triton X-100) and bound utrophin eluted with buffer A containing 100 g/ml FLAG peptide (Sigma-Aldrich). For protein used in rotary shadowing, the M2 column was washed and eluted as described above except that Triton X-100 was omitted. Purified utrophin was concentrated in a Centricon 100 (Amicon, Beverly, MA) and assayed for protein with the Bio-Rad DC protein assay kit by using bovine serum albumin as standard. The typical yield of pure utrophin was 700 g from 5 ϫ 177 cm 2 of cell monolayer. Recombinant utrophin was analyzed on Coomassie blue-stained SDS-polyacrylamide gels and by Western blot analysis with the utrophin-specific monoclonal antibodies MANCHO3 (Man et al., 1991) and DRP-2 (Novocastra, New Castle, UK), and with anti-FLAG clone M2 (Sigma-Aldrich).
Recombinant Utrophin N-Terminal Actin Binding Domains
To generate an expression vector encoding mouse utrophin amino acids 1-261 fused with an amino-terminal FLAG epitope (FLAG-UTR261), the oligonucleotide primers 5Ј-TATTCCGGATTATTCA-TACC-3Ј and 5Ј-GCACCTCTCGAGTTCAATCTAT-3Ј were used to polymerase chain reaction-amplify a cDNA encoding FLAG-UTR261 from the pFASTBAC1 donor plasmid containing fulllength, FLAG-utrophin. The polymerase chain reaction product was subcloned into pCR-Blunt (Invitrogen, Carlsbad, CA), cut out with BamHI and XhoI, and inserted between the BamHI and XhoI sites of pET23 (Novagen, Madison, WI). Both FLAG-UTR261 and an untagged construct (UTR261ϩ) were expressed in Escherichia coli strain BL21 (DE3) and purified by serial ion exchange and gel filtration chromatography essentially as described previously (Moores and Kendrick-Jones, 2000) .
Hydrodynamic Analysis
Measurement of the sedimentation coefficient and Stokes radius and calculation of the native molecular weight and frictional coefficient of recombinant utrophin were performed as described previously (Rybakova and Ervasti, 1997; Amann et al., 1999) .
Electron Microscopy
Recombinant utrophin was diluted 10-fold into 0.15 M ammonium bicarbonate/acetate, pH 7.4, and adjusted to 55% glycerol. Lowangle rotary shadowing and electron microscopy were performed as described previously (Yurchenco and Cheng, 1993) .
Actin Binding Analysis
Recombinant utrophin binding to muscle and nonmuscle F-actin (Cytoskeleton, Denver, CO) was measured as described previously (Rybakova et al., 1996) . Briefly, purified recombinant utrophin or utrophin fragments were incubated with 6 M F-actin in actin binding buffer (10 mM Tris-HCl, pH 8.0, 0.1 mM ATP, 2 mM MgCl 2 , 0.2 mM dithiothreitol, and 0.1% Triton X-100) also containing 100 mM NaCl and centrifuged at 100,000 ϫ g for 20 min. The resulting supernatants and F-actin pellets were resolved on Coomassie bluestained SDS-polyacrylamide gels and the amount of bound and free protein measured by densitometry. The effect of utrophin on F-actin depolymerization was assessed by high-speed cosedimentation after dilution into low ionic strength buffer as described previously (Rybakova et al., 1996; Rybakova and Ervasti, 1997) . Briefly, various concentrations of utrophin were preincubated for 20 min with Factin in actin binding buffer containing 30 mM NaCl and then diluted with actin binding buffer to final actin and NaCl concentrations of 2 M and 4.5 mM, respectively. At various times postdilution, samples were centrifuged and analyzed for the fraction of actin remaining in the pellet as described above. microscopy as described previously (Rybakova et al., 2000) . F-actin was detected with Alexa568-phalloidin (Molecular Probes) and utrophin was stained with rabbit 56 antiserum (Rybakova et al., 2000) or monoclonal antibody (mAb) DRP1 (Novocastra).
Quantitation of Utrophin Protein Expression in Muscle
Trunk and limb muscles of C57BL/10ScSn control (Jackson Laboratories, Bar Harbor, ME), mdx, and Fiona transgenic mdx mice were snap frozen in liquid nitrogen, and stored at Ϫ80°C. Frozen muscle (0.5 g) was pulverized in a mortar and pestle, cooled with liquid nitrogen, and solubilized in 2 ml of 1% SDS, 5 mM EGTA, and a cocktail of protease inhibitors. The samples were incubated for 2 min at 100°C and centrifuged at 12,000 ϫ g. The protein concentration of the supernatants was measured with the Bio-Rad DC protein assay kit by using bovine serum albumin as standard. Nitrocellulose transfers containing various amounts of protein were incubated with a 1:200 dilution of mAb MANCHO3 (Man et al., 1991) and immunoreactivity was detected with 125 I-goat anti-mouse IgG and autoradiography. The intensities of immune signal were analyzed densitometrically. A standard curve of purified recombinant utrophin was included on all gels/transfers.
RESULTS
Expression, Purification, and Characterization of Recombinant Utrophin
The actin binding properties of utrophin have only been extrapolated from studies of small recombinant fragments (Winder et al., 1995; Amann et al., 1999; Moores and Kendrick-Jones, 2000; Zuellig et al., 2000) . Therefore, we generated a baculovirus construct encoding full-length mouse utrophin with an amino-terminal FLAG epitope ( Figure 1A ). Coomassie blue-stained gels of infected cell lysates ( Figure  1B ) revealed a novel protein with an average molecular weight of 379,000. The protein was confirmed as intact FLAG-tagged utrophin on Western blots stained with antibodies to either the amino or carboxyl termini of utrophin and by M2 antibody to the FLAG epitope ( Figure 1 , A and B). Both the anti-FLAG and utrophin amino-terminal, but not the carboxy-terminal antibodies also reacted with a second band of ϳ300,000 molecular weight ( Figure 1B) , which was probably a proteolytic fragment. Recombinant utrophin was purified using anti-Flag M2 agarose chromatography ( Figure 1C ). Densitometry indicated that full-length utrophin comprised ϳ95% of the recovered protein. The remaining ϳ5% was due to the ϳ300,000 molecular weight proteolytic fragment ( Figure 1C ). From the measured Stokes' radius (9.1 nm) and sedimentation coefficient (10.4 S), we calculated a native molecular weight of 404,000 for recombinant utrophin, which was within ϳ3% of its predicted molecular weight of 393,000. The calculated frictional coefficient (1.86) suggested that purified recombinant utrophin assumed an asymmetric rod shape as predicted previously (Tinsley et al., 1992) .
Although dystrophin and utrophin are widely envisioned as highly flexible rod-shaped molecules, the experimental evidence in support of such a model is minimal (Pons et al., 1990) . Therefore, we examined recombinant utrophin by electron microscopy after rotary shadowing (Figure 2 ). The distribution of molecules was sparse due to the marginal solubility of utrophin in the buffer necessary for rotary shadowing. However, the observed molecules predominantly appeared as highly elongated structures with an average contour length of 118 Ϯ 22 nm (Ϯ SD, n ϭ 59). Based on available molecular dimensions (Yan et al., 1993; Keep et al., 1999) , the amino-terminal actin binding domain and 22 spectrin-like repeats of utrophin would be expected to span a length of 115 nm. The globular structure near one end of most molecules may represent the cysteine-rich and C-terminal domains of utrophin because these domains were absent from the proteolytic fragment in purified utrophin (Figure 1 ) and the cysteine-rich domain of dystrophin adopts a globular structure (Huang et al., 2000) . Finally, the molecules displayed random bends or kinks throughout their length, suggesting that utrophin is very flexible.
Actin Binding Properties of Recombinant Utrophin
High-speed cosedimentation analysis demonstrated that recombinant utrophin bound saturably to skeletal muscle Factin with a K d of 0.15 Ϯ 0.06 M and a B max of 1 mol of utrophin/14 mol of actin, whereas virtually no utrophin sedimented in the absence of F-actin (Figure 3, A and B) . Utrophin bound nonmuscle actin with a similar K d of 0.24 Ϯ 0.03 M, indicating no marked preference for different actin isoforms. A recombinant protein encoding utrophin amino acids 1-261 fused with an amino-terminal FLAG epitope (FLAG-UTR261) and an untagged construct (UTR261ϩ) both bound F-actin with 1:1 stoichiometry and K d values of 16.5 Ϯ 5.1 and 7.1 Ϯ 4.1 M, respectively. Thus, the FLAG epitope cannot account for the dramatic differences in actin binding properties between full-length utrophin and the isolated amino-terminal actin binding domain. Most interesting, the surprisingly high affinity and low stoichiometry of full-length utrophin binding to F-actin indicate that the rod domain also participates in utrophin binding to actin.
Because only two spectrin repeats in utrophin are basic, it seemed likely that the utrophin rod domain participates in actin binding through a nonelectrostatic mechanism. We found that utrophin binding to F-actin was insensitive to NaCl concentrations up to 0.8 M ( Figure 3C ). In contrast, dystrophin binding to F-actin was significantly inhibited by 0.5 M NaCl (Rybakova et al., 1996) . Utrophin would also be expected to significantly slow the depolymerization of actin filaments as shown previously for dystrophin (Rybakova et al., 1996) . As predicted, we found that F-actin depolymerization was significantly slowed in the presence of utrophin ( Figure 4A ). However, the protective effect of utrophin on actin depolymerization was more transient, lasting only 80 min compared with dystrophin, which persisted for at least 4 h (Rybakova et al., 1996) . The protective effect of utrophin on F-actin depolymerization saturated at a utrophin: actin molar ratio of 1 utrophin:14 actin monomers ( Figure 4B ), which is highly consistent with the stoichiometry measured at equilibrium. In total, our results suggest that utrophin binds with high affinity along side an actin filament and can stabilize F-actin in vitro in a manner analogous to dystrophin. However, the decreased stoichiometry of utrophin binding to F-actin and its insensitivity to increased ionic strength further suggests that utrophin binds laterally along actin filaments through molecular contacts that are distinct from those used by dystrophin.
Utrophin Overexpression Rescues Costameric Actin Defect of mdx Muscle
We recently demonstrated that a population of actin filaments colocalized with dystrophin in a costameric pattern on sarcolemma peeled from single myofibers of normal mouse muscle (Rybakova et al., 2000) . In contrast, costameric actin was uniformly absent from sarcolemma of dystrophindeficient mdx muscle even though utrophin was markedly up-regulated and retained in a costameric pattern (Rybakova et al., 2000) . We have now peeled sarcolemma from myofibers of a transgenic mdx mouse line (Fiona) that overexpresses full-length utrophin to levels that correct all other phenotypic parameters associated with dystrophin deficiency (Tinsley et al., 1998) . Strikingly, 18 of 19 sarcolemma from two different Fiona mice displayed bright phalloidin staining in a well organized costameric pattern that closely overlapped with utrophin ( Figure 5 ). The one Fiona sarcolemma without phalloidin staining also failed to exhibit any utrophin immunoreactivity. In contrast to the uniform retention of costameric actin on sarcolemma from the Fiona line, phalloidin staining was absent in nine of nine sarcolemma from two age-matched mdx mice, although costameric utrophin was present on all specimens ( Figure 5) . Thus, when overexpressed to sufficiently high levels, utro- 
Quantitation of Utrophin Expression in Control, mdx, and Fiona Mice
Based on our results, utrophin can perform all of the in vitro and in vivo actin binding functions previously documented for dystrophin. However, it remained unclear how much utrophin is required to correct the mdx phenotype relative to the amount of dystrophin normally expressed in wild-type muscle. Therefore, we measured utrophin abundance in skeletal muscle of control, mdx, and Fiona mice by quantitative Western blot analysis with recombinant utrophin as a standard (Figure 6 ). Both the 43-kDa actin-containing band and the 205-kDa myosin heavy chain band exhibited nearly identical densitometric intensities on Coomassie bluestained gels when equal amounts of total protein were loaded for control, mdx, and Fiona muscle ( Figure 6A ). Furthermore, Western blots loaded with equal amounts of total muscle protein for each mouse line yielded nearly identical autoradiographic intensities when stained with a mAb specific for ␣-sarcomeric actin and detected with 125 I-goat antimouse secondary ( Figure 6A ). For utrophin, however, we found it necessary to load different amounts of protein from the three mouse lines to ensure that immune signals from each were measured in the linear range ( Figure 6B ). Control muscle exhibited the lowest utrophin abundance (0.00058 Ϯ 0.000053%), whereas the highest utrophin level was measured in Fiona muscle (0.014 Ϯ 0.0015%). In good agreement with previous measurements of relative abundance (Matsumura et al., 1992; Porter et al., 1998) , the utrophin content of mdx muscle (0.0013 Ϯ 0.00014%) was approximately twofold greater than that of control muscle. Interestingly, the absolute utrophin abundance of mdx muscle was Ͼ60% of a previous estimate of dystrophin abundance in control muscle (Hoffman et al., 1987) . Because the bulk of utrophin immunoreactivity in normal skeletal muscle cross sections is localized to nonmuscle cell types (Rivier et al., 1997; Peters et al., 1998) , it could be argued that utrophin abundance in mdx muscle should be corrected by subtracting the amount of utrophin expressed in normal muscle (0.00058%). Even with this correction, however, our results suggest that the utrophin content of mdx muscle (0.00072%) approaches one-third of the measured dystrophin abundance (0.002%) in normal muscle (Hoffman et al., 1987) .
DISCUSSION
Studies in knock-out and transgenic mice have provided compelling evidence that utrophin can compensate for many mined densitometrically from Coomassie blue-stained gels of supernatant and pellet fractions. Symbols represent data from two independent experiments performed with different utrophin preparations. Nonlinear regression analysis yielded a K d value of 0.2 M and a B max value of 1 utrophin:14 actin monomers. (C) Utrophin (0.2 M) was incubated with 6 M F-actin over a range of NaCl concentrations (0.1-0.8 M) and subjected to centrifugation at 100,000 ϫ g. The binding data (n ϭ 3) were normalized against the amount of actin pelleted and expressed as the percentage of utrophin cosedimented with F-actin in 0.1 M NaCl. Coomassie blue-stained SDS-polyacrylamide gel of the supernatant (S) and pellet (P) recovered after 0.6 M recombinant utrophin (rUTR) was centrifuged at 100,000 ϫ g in the presence or absence of 6 M skeletal muscle F-actin (ACT). (B) Increasing concentrations of recombinant utrophin were incubated with 6 M F-actin with subsequent centrifugation. The amount of free and actin-bound utrophin was deter-I.N. Rybakova et al. of the functions normally performed by dystrophin in skeletal muscle (Tinsley et al., , 1998 Deconinck et al., 1997a, b; Grady et al., 1997) . Herein, we have demonstrated that utrophin can retain costameric actin on mechanically peeled sarcolemma when overexpressed in mdx muscle to levels that also correct all other known parameters of the mdx phenotype. These results simultaneously validate the costameric actin defect of mdx sarcolemma (Rybakova et al., 2000) as a direct consequence of dystrophin deficiency and reinforce the hypothesis that utrophin and dystrophin are functionally interchangeable.
Given the differences between analogous domains in primary structure (Winder, 1997; Amann et al., 1999) and actin binding properties (Winder et al., 1995; Amann et al., 1998 Amann et al., , 1999 Renley et al., 1998; Moores and Kendrick-Jones, 2000) , it was expected that utrophin would bind actin filaments through a mechanism distinct from the lateral attachment used by dystrophin. Surprisingly, we have demonstrated that recombinant utrophin bound actin filaments with significantly higher affinity and through a more extensive lateral association than was anticipated. Our experiments indicate that full-length utrophin can occupy 14 actin monomers when saturating an actin filament compared with the one-to-one association consistently observed with the isolated utrophin amino-terminal actin binding domain (Moores and Kendrick-Jones, 2000) . Our previous studies (Rybakova et al., 1996; Rybakova and Ervasti, 1997; Amann et al., 1999) indicated that 17 spectrin repeats allow dystrophin to associate with 24 monomers in an actin filament (Figure 7) . Assuming that a similar repeat/actin monomer ratio holds for utrophin, our data predict that perhaps the first 10 spectrin-like repeats participate in the actin binding activity of utrophin (Figure 7) . Interestingly, a recombinant protein corresponding to the amino-terminal actin binding domain and first 2.5 spectrin-like repeats of utrophin (Zuellig et al., 2000) bound F-actin with an affinity (2 M) and stoichiometry (1:5) intermediate to that observed for the . F-actin was preincubated alone or in a 10:1 M ratio with utrophin and filament depolymerization was induced by dilution to final actin and NaCl concentrations of 2 M and 4.5 mM, respectively. At various times postdilution, samples were centrifuged at 100,000 ϫ g for 20 min and the fraction of F-actin remaining was determined densitometrically from Coomassie blue-stained gels loaded with equal volumes of supernatants and pellets. Time points include centrifugation time. (B) F-actin was preincubated with increasing amounts of utrophin to give the indicated utrophin/actin monomer ratio and depolymerization was initiated by dilution as described above. Thirty minutes after initiation of depolymerization, samples were centrifuged at 100,000 ϫ g and the percentage of F-actin remaining was determined as in A. The data represent the average (Ϯ SEM) from five (A) and three (B) independent experiments. . Although we are not aware of any studies that have explicitly tested whether the C-terminal region of utrophin binds to F-actin, the homologous region of dystrophin failed to bind F-actin as assessed by high-speed cosedimentation (Corrado et al., 1994) . Moreover, we previously detected no F-actin cosedimentation by the C-terminal dystrophin fragment or dystrophin associated proteins after calpain digestion of purified dystrophinglycoprotein complex (Rybakova et al., 1996) . Finally, dystrophin and utrophin would be expected to bind actin filaments with similar stoichiometries if they bound filaments through N-and C-terminal binding sites. However, our data indicate that utrophin interacts with fewer actin monomers in filaments compared with dystrophin. Based on current data, we propose that the actin binding region of utrophin spans from its amino terminus through repeat 10, whereas that of dystrophin extends out through repeat 17 (Figure 7 ). The participation of 10 spectrin-like repeats in utrophin binding to F-actin may explain why a utrophin construct lacking repeats 4 -19 was less effective than fulllength utrophin in ameliorating the phenotypes associated with dystrophin deficiency in mdx mice (Deconinck et al., 1997b; Tinsley et al., 1998) . Because the utrophin rod domain lacks a cluster of basic, spectrin-like repeats (Amann et al., 1999) , it is likely that utrophin repeats interact with actin filaments through a molecular mechanism that is distinct from the electrostatic interaction used by the dystrophin middle rod domain . Indeed, we observed that utrophin binding to F-actin was insensitive to NaCl concentrations (Figure 4 ) that significantly inhibited dystrophin binding to F-actin (Rybakova et al., 1996) . A contribution by the spectrin-like repeats most proximal to the N-terminal actin binding activity of utrophin and dystrophin may explain why dystrophin constructs containing only five spectrin-like repeats can rescue the mdx phenotype (Wang et al., 2000) , whereas constructs lacking the entire rod domain failed to provide functional correction (Hartigan-O'Connor and Chamberlain, 2000) . Our results further imply that the actin side binding function now demonstrated for vertebrate dystrophin and utrophin may be more widely conserved across invertebrate dystrophin family members than could be predicted by sequence comparisons (Greener and Roberts, 2000; Neuman et al., 2001 ). More generally, we speculate that the combined presence of a CH-type actin binding domain and spectrin-like repeats may enable some members of the plakin family of cytolinkers to laterally bind and stabilize actin filaments (Leung et al., 2001) . In support of this possibility, actin filaments associated with microtubule-bound microtubule actin crosslinking factor (MACF) were recently found to be more resistant to depolymerization induced by latrunculin B (Karakesisoglou et al., 2000) .
We have also made use of purified recombinant utrophin as a standard to estimate the absolute utrophin protein content in control, mdx, and the Fiona line of transgenic mice. The utrophin content of Fiona muscle was ϳ10-fold greater than that of mdx muscle and also approximately sevenfold greater than the dystrophin content of control muscle (Hoffman et al., 1987) . A 50-fold overexpression of dystrophin was previously shown to correct the mdx phenotype without any toxic side effects (Cox et al., 1993) . At present, it is not possible to determine the minimal level of utrophin expression necessary for retention of costameric actin on isolated sarcolemma, or for full correction of the dystrophic phenotype. However, utrophin expression in mdx muscle was greater than 60% of a similarly determined estimate of dystrophin content in striated muscle from normal mice (Hoffman et al., 1987) . Even after correction for nonmuscle utrophin expression, our current measurements indicate that mdx muscle up-regulates utrophin expression to 36% of dystrophin levels in normal muscle, which may explain its milder phenotype compared with mice deficient in both dystrophin and utrophin (Deconinck et al., 1997a; Grady et al., 1997) . On the other hand, transgenic expression of dystrophin to 20% of its normal levels was sufficient to prevent essentially all dystrophic symptoms in the mdx mouse (Phelps et al., 1995) . Thus, the presence of even mild phenotype despite significant levels of utrophin in mdx muscle can be interpreted several ways. First, the increased utrophin expression of mdx muscle may be preferentially concentrated within regenerating fibers although weak sarcolemmal utrophin staining is sometimes apparent in large diameter mdx muscle fibers with peripheral nuclei (Peters et al., 1997) . It is also possible that utrophin is less efficient in coupling the sarcolemma to costameres. Based on our depolymerization experiments, utrophin/F-actin complexes may be kinetically less stable compared with dystrophin/F-actin complexes (Rybakova et al., 1996) , whereas other results (Lumeng et al., 1999; Imamura et al., 2000) suggest that the utrophin/␤-dystroglycan interaction may be weaker. Alternatively, correction of the mdx phenotype by transgenic dystrophin expression to 20% of wild-type levels (Phelps et al., 1995) may instead have been due to functional additivity with concomitant up-regulation of utrophin. Likewise, rescue of the mdx phenotype by truncated dystrophins (Wang et al., 2000) may be due in part to additivity with the high utrophin levels endogenous to mdx muscle. Functional additivity further suggests that even low-level dystrophin expression induced by gene therapy when combined with pharmacological up-regulation of endogenous utrophin expression may yield an additive therapeutic benefit in patients with dystrophinopathies.
Due mainly to its exceedingly low abundance in native tissues, the biochemical characterization of utrophin function has previously relied on analysis of recombinant protein fragments (Winder et al., 1995; Amann et al., 1999; Chung and Campanelli, 1999; James et al., 2000) . Our actin binding studies of full-length recombinant utrophin suggest that the sum of the parts does not necessarily equal, or even accurately reflect the behavior of the whole. Future experiments will revisit models for the interaction between utrophin/dystrophin and ␤-dystroglycan, which currently rely almost exclusively on results with isolated protein fragments (Chung and Campanelli, 1999; Huang et al., 2000; James et al., 2000) . Full-length recombinant utrophin will also be an invaluable probe to identify novel molecular partners. Finally, the utrophin prepared by these methods now make possible studies to characterize its mechanical properties at the level of single molecules (Rief et al., 1999) .
